Navigation Links
Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
Date:11/25/2009

BASKING RIDGE, N.J., Nov. 25 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that David Mazzo, PhD, CEO and President, will be presenting at the Piper Jaffray 21st Annual Health Care Conference at the New York Palace Hotel in New York City. Dr. Mazzo's presentation will be given at 1:10pm (EST) on Tuesday, December 1 and will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1. The healthcare industry's leading senior management teams will be presenting at this conference to top institutional investors, equity portfolio managers and research analysts worldwide.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1, presently in phase 2b clinical trial, is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention. REG2, Regado's second product candidate, consists of a subcutaneously administered formulation of RB006 paired with the IV bolus formulation of RB007. REG2 is currently undergoing phase 1 clinical testing and is intended for use in venous thrombosis indications.

ABOUT APTAMERS

RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein. A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing it biologic effects.

More information can be found at http://www.regadobio.com

SOURCE Regado Biosciences


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
2. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
3. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
4. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
5. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
6. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
7. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
8. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
9. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... May 26, 2017  Endo International plc (NASDAQ: ... and CEO, will represent the Company in a fireside chat ... on Tuesday, June 13, 2017 at 10:40 a.m. PT / ... Resort in Rancho Palos Verdes, CA. ... event will be available on the Company,s website at ...
(Date:5/26/2017)... 2017  In response to the opioid epidemic in ... is working with Pfizer to make up to 1 ... to community health centers, free and charitable clinics, public ... "Pfizer has a long-standing commitment to improving health ... safety through educational activities," said Caroline Roan , ...
(Date:5/24/2017)... 24, 2017  ivWatch LLC today announced the ... Board to enable seamless integration of ivWatch,s groundbreaking ... infusion pumps and other devices. By integrating ivWatch ... to help health care customers deliver a higher ... to IV therapy. "The ivWatch OEM ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... Mediaplanet is proud to announce the launch of its ... will educate readers on how to take care of all aspects of their skin. ... on melanoma. Dancing with the Stars professional, Witney Carson, shares her journey with the ...
(Date:5/26/2017)... ... May 26, 2017 , ... The American ... review more than eighty-nine grant submissions all vying for nearly $1,000,000 in funding ... Parkinson’s field.     , The American Parkinson Disease Association (APDA) is focused on advancing ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... Boston CEO 2017 on May 30th and 31st at The Four Seasons Hotel ... leading executives in the life sciences, offering exclusive access to key decision makers ...
(Date:5/26/2017)... ... May 26, 2017 , ... The ... educational seminar to focus on current legislative activity and the latest regulatory concerns ... 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. 11, at ...
(Date:5/26/2017)... ... 26, 2017 , ... Amir Qureshi, MD is the first physician in Arkansas ... stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a treatment ... in Arkansas to introduce the most powerful SCS system and the only stretchable lead ...
Breaking Medicine News(10 mins):